Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?
Guillaume Canaud(Université Paris Cité), Christophe Legendre(Hôpital Necker-Enfants Malades)
Cited by 68
Related Papers
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
|American Journal of Transplantation|2016|625
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
|Clinical Pharmacology & Therapeutics|2010|363
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation
|Science Translational Medicine|2014|231
Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients
|Clinical Pharmacology & Therapeutics|2009|126